Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Gains from Investment Securities (2016 - 2023)

Ovid Therapeutics filings provide 8 years of Gains from Investment Securities readings, the most recent being $12000.0 for Q4 2023.

  • Quarterly Gains from Investment Securities fell 99.92% to $12000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $12000.0 through Sep 2024, down 99.92% year-over-year, with the annual reading at $15.8 million for FY2022, 46.54% up from the prior year.
  • Gains from Investment Securities hit $12000.0 in Q4 2023 for Ovid Therapeutics, up from -$12000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.8 million in Q4 2022 and bottomed at -$15.8 million in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $2.3 million, with a median of $11000.0 recorded in 2020.
  • Peak annual rise in Gains from Investment Securities hit 230733.43% in 2022, while the deepest fall reached 244.06% in 2022.
  • Ovid Therapeutics' Gains from Investment Securities stood at $7.4 million in 2019, then crashed by 106.6% to -$488384.0 in 2020, then surged by 310.17% to $1.0 million in 2021, then surged by 1444.08% to $15.8 million in 2022, then tumbled by 99.92% to $12000.0 in 2023.
  • Per Business Quant, the three most recent readings for OVID's Gains from Investment Securities are $12000.0 (Q4 2023), -$12000.0 (Q1 2023), and $15.8 million (Q4 2022).